378
Participants
Start Date
October 16, 2017
Primary Completion Date
October 13, 2020
Study Completion Date
December 31, 2025
IMCgp100
IMCgp100 is to be administered at 20 mcg cycle 1 day1, then 30 mcg cycle 1 day 8, then 68 mcg cycle 1 day 15 and weekly thereafter by IV infusion over 15 minutes until confirmed disease progression or unacceptable toxicity
Dacarbazine
Dacarbazine is to be administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity
Ipilimumab
Ipilimumab is to be administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments
Pembrolizumab
Pembrolizumab is to be administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity
Saint Vincents Hospital, Darlinghurst
LUMC Medical Oncology, Leiden
Peter MacCallum Cancer Center, Melbourne
Central Adelaide Local Health Network, Royal Adelaide Hospital Cancer Center, Adelaide
Centre Atoine Lacassagne, Nice
University of Zurich Hospital, Zurich
Uzhhorod Central City Clinical Hospital, Uzhhorod
Columbia University Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Roswell Park Cancer Institute, Buffalo
University of Pittsburgh Medical Center, Pittsburgh
Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela
Thomas Jefferson University Hospital, Philadelphia
Fondazione ICCRS, Milan
University of Hamburg, Hamburg
Duke University Health System, Durham
Hospital Universitario La Paz, Madrid
Winship Cancer Institute of Emory University, Atlanta
University of Miami - Sylvester Comprehensive Cancer Center, Miami
Hospital Universitario Virgen Macarena, Seville
The Ohio State University, Columbus
Hospital Universitario General de Valencia, Valencia
Dnipropetrovsk State Medical Academy, Dnipro
Universitaetsklinikum Koeln Dermatologie und Venerologie, Cologne
University of Iowa, Iowa City
Northwestern University, Chicago
The University of Chicago Medicine, Chicago
Washington University School of Medicine, St Louis
Nationales Centrum für Tumorerkrankungen, Heidelberg
University of Oklahoma, Oklahoma City
Institut Curie, Paris
Houston Methodist Cancer Center, Houston
University of Colorado, Aurora
"Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - UOC Melanoma, Immunoterapia Oncologica e Terapie Innovative", Napoli
Klinik und Poliklinik für Dermatologie und Allergologie, Munich
UCLA Medical Center, Los Angeles
The Angeles Clinic and Research Institute, Los Angeles
California Pacific Medical Center, San Francisco
Byers Eye Institute, Stanford University, Palo Alto
Portland Providence Medical Center, Portland
Federal State Budgetary Institution N.N. Blokhin National Medical Research Center of Oncology, Moscow
Federal State Budget Institution National Medical Research Center of Oncology, Saint Petersburg
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Institut Roi Albert II Cliniques Universitaires St-Luc, Brussels
Universite Catholique de Louvain Centre du Cancer, Medical Oncology, Brussels
University Hospital Essen, Essen
Cross Cancer Institute, Edmonton
Princess Margaret Cancer Centre, Toronto
Charite - Campus Benjamin Franklin, Berlin
Universitätsklinikum Carl Gustav Carus, Dresden
Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie, Warsaw
Institut Catala d'Oncologia (ICO) - L'Hospitalet, L'Hospitalet de Llobregat
Kyiv Munitipal Hospital, Kyiv
Mount Vernon Cancer Centre, Northwood
The Clatterbridge Cancer Centre, Bebington
Beatson West of Scotland Cancer Centre, Glasgow
Lead Sponsor
Immunocore Ltd
INDUSTRY